Presentation is loading. Please wait.

Presentation is loading. Please wait.

Nat. Rev. Neurol. doi: /nrneurol

Published bySpencer Nelson Modified over 6 years ago

Similar presentations

Presentation on theme: "Nat. Rev. Neurol. doi: /nrneurol"— Presentation transcript:

1 Nat. Rev. Neurol. doi:10.1038/nrneurol.2017.88
Figure 3 Common problems with the interpretation of pharmacogenetic studies in CIPN Figure 3 | Common problems with the interpretation of pharmacogenetic studies in CIPN. Several methodological drawbacks of chemotherapy-induced neuropathy (CIPN) pharmacogenetic trial design should be improved in future studies, to enable the management of CIPN to be informed by genetic associations. GWAS, genome-wide association study; SNP, single nucleotide polymorphism. Argyriou A. A. et al. (2017) Chemotherapy-induced peripheral neurotoxicity: management informed by pharmacogenetics Nat. Rev. Neurol. doi: /nrneurol

Download ppt "Nat. Rev. Neurol. doi: /nrneurol"

Similar presentations

Table 3 Limb-girdle muscular dystrophy standardized data collection form and HPO mapping Thompson, R. & Straub, V. et al. (2016) Limb-girdle muscular dystrophies.

Table 3 Limb-girdle muscular dystrophy standardized data collection form and HPO mapping Thompson, R. & Straub, V. et al. (2016) Limb-girdle muscular dystrophies.
Nat. Rev. Neurol. doi:10/1038/nrneurol

Nat. Rev. Neurol. doi:10/1038/nrneurol
Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol
Figure 4 Progression-free survival, according to treatment group

Figure 4 Progression-free survival, according to treatment group
Figure 3 Life expectancy at birth in all countries included

Figure 3 Life expectancy at birth in all countries included
Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol
Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol
Figure 2 The US Centers for Disease Control and

Figure 2 The US Centers for Disease Control and
Figure 4 Time course of the development of physiological changes

Figure 4 Time course of the development of physiological changes
Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol
Figure 1 Carotid artery inflammation detected using 18F-FDG-PET

Figure 1 Carotid artery inflammation detected using 18F-FDG-PET
Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol
Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol
Figure 2 Overview of risk factors for Parkinson disease dementia

Figure 2 Overview of risk factors for Parkinson disease dementia
Figure 1 Mendelian randomization study

Figure 1 Mendelian randomization study
Figure 2 Copy-number variations in multiple myeloma

Figure 2 Copy-number variations in multiple myeloma
Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol
Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol
Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum
Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Similar presentations

Ads by Google